Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046793 | 0.89 | NR4A2 (0.47) | NR4A2CREBBPGRM1MAP2K1 | |
| SCHEMBL6022276 | 0.85 | NR4A2 (0.41) | NR4A2CREBBPGRM1LMNAMAP2K1 | |
| SCHEMBL12529489 | 0.82 | GRM1 (0.53) | GRM1 | |
| SCHEMBL6023948 | 0.82 | NOTUM (0.46) | GRM1 | |
| SCHEMBL8196733 | 0.81 | NR4A2 (0.45) | NR4A2CREBBPLMNAMAP2K1 | |
| SCHEMBL6023612 | 0.80 | GRM1 (0.42) | NR4A2CREBBPGRM1MAP2K1 | |
| SCHEMBL9400147 | 0.79 | NR4A2 (0.49) | NR4A2CREBBPLMNAMAP2K1 | |
| SCHEMBL11201376 | 0.78 | NPSR1 (0.43) | NR4A2CREBBPGRM1MAP2K1 | |
| SCHEMBL1156403 | 0.76 | NR4A2 (0.49) | NR4A2CREBBPLMNAMAP2K1 | |
| SCHEMBL16416410 | 0.74 | CSNK2A1 (0.36) | GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034151-B2 | 1,4-dihydro-4-oxo-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylates; novel approach to the formation of the bicyclic heterocyclic ring system | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1590335-A4 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | CHEN BANG-CHI | 2006-02-23 | — | — | US | disclosed |
| EP-1590335-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004072030-A2 | PROCESS FOR PREPARING PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157846-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | NR4A2 3889/4885CREBBP 947/4885GRM1 1709/4885 |
| US-20060041124-A1 | Process for preparing pyrrolotriazine kinase inhibitors | MAP3K15, MAP4K2, MAP3K5 | NR4A2 3889/4885CREBBP 947/4885GRM1 1709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.